TB-500 and Liver Function: What Women Need to Know Before Using This Peptide

What Is TB-500 and Why Are Women Asking About It?

TB-500 is a synthetic, 17-amino-acid fragment of thymosin beta-4, a naturally occurring protein found in nearly every human cell. It is not FDA-approved. Compounding pharmacies operating under USP 503A regulations produce it for research use or, in some clinical settings, for individual patient prescriptions.

Women are seeking it out for several reasons: accelerated recovery from musculoskeletal injury, potential anti-inflammatory effects, and, more recently, early signals from animal research suggesting benefit in liver disease. That last point deserves careful unpacking, because the distance between a mouse model of liver fibrosis and a woman managing metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is vast.

The Peptide Itself

Thymosin beta-4 (Tβ4) is encoded by the TMSB4X gene located on the X chromosome. Research published in Annals of the New York Academy of Sciences by Goldstein and colleagues in 2012 summarized Tβ4's roles: actin sequestration, anti-inflammation, angiogenesis, and cardiac protection after myocardial infarction in animal models. TB-500 is the fragment corresponding to amino acids 17-23 of the full protein, the region thought to carry most of the tissue-repair signal.

Why This Matters Differently for Women

Women have a distinct liver physiology. Estrogen reduces hepatic de novo lipogenesis, which partly explains why premenopausal women have lower rates of MASLD than age-matched men. CDC surveillance data show that MASLD prevalence rises sharply in women after menopause, when that estrogen-related protection disappears. PCOS, which affects an estimated 6-13% of reproductive-age women globally according to WHO, independently elevates liver enzyme levels and steatosis risk through insulin resistance. Any peptide with a proposed hepatic mechanism therefore needs to be evaluated with this hormonal context in mind, not from a male-default metabolic baseline.

What the Animal Evidence Actually Shows

Animal data on thymosin beta-4 and liver function are more encouraging than most people realize, and more limited than peptide marketing suggests.

Fibrosis Models

In carbon tetrachloride-induced liver fibrosis in rodents, thymosin beta-4 administration was associated with reduced collagen deposition and lower serum alanine aminotransferase (ALT) compared to vehicle-treated controls. A 2013 study in PLOS ONE (PMID 24349160) demonstrated that exogenous Tβ4 suppressed hepatic stellate cell activation and reduced TGF-beta1 expression, two of the core drivers of hepatic fibrosis. The effect size in that model was meaningful: ALT fell by roughly 40% and liver hydroxyproline content (a marker of collagen) fell by approximately 35% compared to controls.

NASH and Steatosis Models

Separate rodent work in diet-induced NASH showed that Tβ4 modulated the NLRP3 inflammasome pathway, reducing hepatic interleukin-1beta secretion. One murine study (PMID 29079464) reported improvement in NAFLD Activity Score alongside lower fasting insulin, which is directly relevant to PCOS-associated steatosis in women. The insulin-sensitizing signal was modest and has not been replicated in humans.

The Actin-Sequestration Mechanism

Tβ4 binds G-actin in a 1:1 ratio, preventing its polymerization into F-actin. This is not simply a healing trick. Inside hepatocytes under oxidative stress, dysregulated actin dynamics contribute to cell death and cytoskeletal collapse. By buffering the free G-actin pool, Tβ4 may protect hepatocyte architecture during injury. This mechanism is biologically plausible and directly studied in liver cell lines, but whether the compounded TB-500 fragment reproduces this at subcutaneous doses used clinically is not established in humans.

What the Human Evidence Does (and Does Not) Show

Here is where you need plain language. There are no published randomized controlled trials of TB-500 in humans with liver disease. None.

The Goldstein 2012 paper, the most frequently cited human-adjacent reference, focused on cardiac repair after myocardial infarction. It documented tolerability and initial efficacy signals in a small Phase II cardiac trial (STAT trial, n=72), not liver outcomes. That publication does not mention hepatic enzyme changes or liver function tests. Citing it as evidence for liver benefit is an extrapolation that is not supported by the text.

Liver Function Tests in Compounded Peptide Users

No prospective trial has systematically tracked ALT, AST, alkaline phosphatase, GGT, or bilirubin in a cohort of women using compounded TB-500. What exists instead are scattered case reports and bodybuilding community self-reports, which carry the highest possible risk of confounding (concurrent anabolic steroid use, unreported supplements, variable product purity).

The WomanRx TB-500 Liver Monitoring Framework is our clinical team's structured approach to risk-stratifying women who present asking about this peptide. It does not appear in any published guideline because no guideline addresses compounded TB-500 specifically.

| Risk tier | Profile | Recommended baseline labs before any use | |-----------|---------|------------------------------------------| | Tier 1: Standard | Healthy premenopausal woman, no metabolic conditions | ALT, AST, GGT, total bilirubin, CBC | | Tier 2: Elevated | PCOS, insulin resistance, BMI >30, or perimenopausal | All Tier 1 labs plus fasting insulin, HbA1c, lipid panel, hepatic ultrasound | | Tier 3: High | Known steatosis, elevated baseline ALT, alcohol use, or hepatotoxic medication co-use | Defer TB-500 until hepatology clearance; risk-benefit almost always unfavorable |

This framework reflects the clinical judgment of the WomanRx editorial board and is not derived from a published protocol.

The Evidence Gap Is a Women's-Health Issue

Women have been historically underrepresented in peptide and tissue-repair trials. The STAT cardiac trial enrolled predominantly male post-MI patients. A 2021 NIH analysis found that women remain underrepresented in cardiovascular peptide research despite accounting for nearly half of heart failure deaths. What this means practically: we are extrapolating male-derived PK data to female bodies with different estrogen-driven hepatic enzyme induction, different body composition, and different drug distribution volumes. That is a meaningful uncertainty, and any clinician or source that does not acknowledge it is not giving you the full picture.

Sex-Specific Pharmacokinetics: What We Know and What We're Guessing

Thymosin beta-4 is a small peptide (molecular weight approximately 4,921 Da). It is cleared by proteolytic degradation rather than hepatic CYP450 enzymes, which is one reason early investigators hoped it would have a favorable liver safety profile.

Estrogen Interactions

Estrogen upregulates certain hepatic peptide transporters and modulates the NLRP3 inflammasome, the same pathway Tβ4 appears to affect in NASH models. In theory, a premenopausal woman with normal estradiol levels might have different hepatic pharmacodynamics than a postmenopausal woman on no hormone therapy. This has not been studied directly. After menopause, the loss of estrogen-driven hepatic protection means that any hepatotoxic signal, even a subtle one, could have greater clinical consequence.

Menstrual Cycle Phase

Peptide volume of distribution and renal clearance vary across the menstrual cycle because progesterone affects renal sodium handling and plasma volume changes by 5-10% between follicular and luteal phases. This is unlikely to produce clinically meaningful TB-500 concentration differences at typical compounded doses, but it means that liver enzyme tests drawn in the luteal phase may differ from those drawn in the follicular phase, independent of the drug. Standardizing monitoring labs to cycle day 2-5 (early follicular) removes that confound.

PCOS-Specific Considerations

Women with PCOS frequently have baseline ALT elevations driven by insulin resistance and hepatic steatosis, independent of any drug use. A meta-analysis published in Fertility and Sterility found that women with PCOS had significantly higher rates of NAFLD (odds ratio approximately 3.93) compared to controls. Starting TB-500 with an already-elevated baseline ALT makes it nearly impossible to interpret subsequent enzyme changes as drug-related versus disease-progression-related. Baseline imaging is not optional in this population.

Pregnancy, Lactation, and Contraception

TB-500 is contraindicated in pregnancy. This is non-negotiable, not a nuanced discussion.

There are no human pregnancy safety data for thymosin beta-4 or the TB-500 fragment. The FDA has not assigned a formal pregnancy category because the compound has never completed the approval pathway. Based on animal reproductive toxicology, Tβ4 promotes angiogenesis and cell migration. Those same mechanisms that might repair tissue in an adult woman could theoretically interfere with normal placentation, trophoblast invasion, or embryonic vascular development. No one has studied this directly because it would be unethical to do so prospectively.

ACOG guidance on compounded bioidentical and peptide hormones consistently advises that compounded agents with no reproductive safety data should not be used during pregnancy or while attempting to conceive. TB-500 falls squarely in that category.

What to Do If You Are Trying to Conceive

Stop TB-500 at least three months before attempting conception. This is a conservative interval based on general peptide clearance kinetics and the absence of reassuring reproductive data, not on a specific published washout study for this compound. If you are using TB-500 and not actively trying to prevent pregnancy, you need reliable contraception. An intrauterine device or hormonal method that does not require daily adherence is preferable.

Lactation

Transfer of the TB-500 fragment into breast milk is unknown. Peptides are generally degraded in the neonatal gastrointestinal tract if they do transfer, but this cannot be assumed for all peptide structures, and maternal systemic exposure is real. Until transfer data exist, the conservative position is to pause use during breastfeeding and for at least 72 hours after the last dose if resuming is considered. Discuss this with a WomanRx clinician before making that decision.

Contraception Requirements

If you are prescribed compounded TB-500 by a licensed clinician and are of reproductive age, you should be on reliable contraception for the duration of use. Document this conversation in your medical record. A prescribing clinician who does not ask about your pregnancy intentions before writing this prescription is not following standard compounding-prescribing practice.

Who This Peptide May Be Right For (and Who It Is Not)

Potentially Appropriate (Research Context Only)

• Postmenopausal women with documented musculoskeletal injury who have failed standard physical therapy and have normal baseline liver function (Tier 1 profile)
• Women with inflammatory tendinopathy or delayed tissue repair who are not pregnant, not breastfeeding, and are under the care of a prescribing clinician who can monitor labs quarterly
• Research participants enrolled in an IRB-approved protocol where monitoring is built in

Not Appropriate

• Any woman who is pregnant or planning to become pregnant within three months
• Women breastfeeding infants
• Women with elevated baseline ALT (>40 U/L) or known steatosis without hepatology clearance
• Women taking hepatotoxic medications (methotrexate, high-dose acetaminophen, certain antifungals) concurrently
• Women with PCOS and uncontrolled insulin resistance who have not had a baseline hepatic ultrasound
• Women in perimenopause with no recent metabolic panel, given the rising MASLD prevalence in that life stage

What Monitoring Should Look Like If You Proceed

If a licensed clinician determines that compounded TB-500 is appropriate for you, liver function monitoring is not optional. The WomanRx clinical team recommends the following structure, adapted from general peptide prescribing best practices and the compounding pharmacy guidance published by FDA's Center for Drug Evaluation and Research:

Baseline (Before First Dose)

• Complete metabolic panel (CMP): includes ALT, AST, alkaline phosphatase, bilirubin, albumin, and total protein
• GGT (not always included in standard CMP; request specifically)
• Fasting lipid panel
• Fasting insulin and HbA1c if you have PCOS, obesity, or perimenopausal status
• Hepatic ultrasound if any of the above are abnormal or if you have PCOS

At 6 Weeks

• Repeat CMP and GGT
• If ALT rises more than 2x the upper limit of normal from baseline, stop the peptide and recheck in four weeks

At 12 Weeks and Quarterly Thereafter

• Full CMP and GGT
• Clinical review of symptom burden: right upper quadrant discomfort, new fatigue, or jaundice should prompt immediate liver evaluation

A rise in ALT that does not resolve within four weeks of stopping TB-500 suggests a confounding cause and warrants hepatology referral, not re-starting the peptide.

The Regulatory and Purity Question

Compounded TB-500 is not subject to the same manufacturing controls as FDA-approved drugs. A 2023 FDA warning letter database search shows ongoing enforcement actions against compounding pharmacies for sterility failures and mislabeled peptide content. An independent 2021 analysis of commercially available peptides found that approximately 25% of tested vials contained less than 90% of the labeled active compound, and some contained bacterial endotoxins.

This purity question has a direct liver implication. Lipopolysaccharide (endotoxin) contamination activates Kupffer cells in the liver and can cause transient but significant ALT elevations that would be misattributed to the peptide itself rather than manufacturing failure. Requesting a certificate of analysis (CoA) from your compounding pharmacy and verifying that the pharmacy holds a valid 503A registration with your state board of pharmacy is a minimum standard, not a luxury.

Current Clinical Update: Where Research Stands in 2025

As of mid-2025, there is no published Phase II or Phase III human trial of TB-500 specifically targeting liver outcomes. The most active areas of thymosin beta-4 research remain cardiac (the STAT trial follow-on work) and ophthalmologic (dry eye, corneal repair). A search of ClinicalTrials.gov does not return any active trials examining TB-500 and hepatic fibrosis or steatosis in humans as of this writing.

The peptide community's enthusiasm for hepatic applications rests almost entirely on the rodent fibrosis and NASH data described above. That data is interesting. It is not sufficient to recommend clinical use for a liver indication, and any clinician who presents it as proven liver therapy is overstating the evidence.

A 2022 review in Frontiers in Pharmacology (PMID 35462924) noted that Tβ4's pleiotropic mechanisms make it a promising but difficult therapeutic target precisely because the same pathways involved in tissue repair are also involved in oncogenesis and vascular remodeling. Long-term safety data in any population, let alone women at distinct hormonal life stages, do not exist.

The honest clinical position: TB-500 is not ready to be recommended for liver disease. If you have liver enzyme elevations, the priority is identifying the cause (MASLD, PCOS-related steatosis, alcohol, thyroid dysfunction, autoimmune hepatitis) and addressing it with evidence-based approaches before considering a research peptide with this level of uncertainty.